Health
Study finds that proteins may predict who will get dementia in 10 years based on blood samples
A study of frozen blood samples has turned up a trove of proteins that may predict several forms of dementia more than 10 years before the disease is diagnosed, researchers from the U.K. and China reported on Monday.
The study, published in the journal Nature Aging, is part of ongoing research from multiple teams to identify patients at risk for dementia using a simple blood test, an advance many scientists believe will accelerate the development of new treatments.
Currently, brain scans can detect abnormal levels of a protein called beta amyloid many years before Alzheimer’s dementia develops, but the tests are costly and often not covered by insurance.
DEMENTIA AMONG YOUNGER PEOPLE LINKED TO 15 FACTORS, MAJOR STUDY REVEALS
“Based on this study, it does seem likely that blood tests will be developed that can predict risk for developing dementia over the next 10 years, although individuals at higher risk often have difficulty knowing how to respond,” said Dr. Suzanne Schindler, an Alzheimer’s researcher at Washington University in St. Louis, who was not involved in the research.
A new study proved that proteins may be able to predict who will get dementia 10 years prior to a diagnosis. (REUTERS/Denis Balibouse)
Study author Jian-Feng Feng of Fudan University in Shanghai said such tests are critical in aging populations such as China’s, and noted that he is in talks for potential commercial development of a blood test based on their research.
In the study, researchers at the University of Warwick and Fudan University studied 52,645 blood samples from the U.K.’s Biobank research repository, collected between 2006 and 2010 from people who had no signs of dementia at the time.
Of these, 1,417 people eventually developed Alzheimer’s disease, vascular dementia or dementia from any cause. The researchers studied protein signatures common in these individuals and turned up 1,463 proteins associated with dementia and ranked these according to how likely they were to predict dementia.
DEMENTIA’S STAGGERING FINANCIAL COST IS REVEALED IN NEW REPORT: IT’S ‘BANKRUPTING FAMILIES’
They found that people whose blood carried higher levels of the proteins GFAP, NEFL, GDF15 and LTBP2 were consistently more likely to have developed Alzheimer’s disease, vascular dementia or dementia from any cause. People with elevated levels of GFAP were 2.32 times more likely to develop dementia, confirming findings from smaller studies that had pointed to the contribution of this protein.
The authors noted that their research has not been independently validated.
One protein that performed well in predicting dementia, neurofilament light, is already used in the clinic for diagnosing and monitoring some conditions such as multiple sclerosis, Schindler said in an email.
“This study did not include clinically available blood tests for Alzheimer disease, which likely would even better predict development of dementia due to Alzheimer’s disease,” she said.
Such tests are already being used in identifying candidates for clinical trials testing treatments in patients with early-stage or even presymptomatic disease, such as Eisai and Biogen’s Leqembi. The drug recently won regulatory approval in the United States, Japan and China.
Medical expert analyzes trending IV therapy, concerns about peptides
Dr. Mike Varshavski joins ‘Fox & Friends’ for Wellness Week, examining trending self-care treatments. He evaluates IV vitamin therapy, highlighting its hospital-critical role versus unproven benefits for general wellness, citing potential risks like vitamin imbalance. Dr. Mike also differentiates creatine, a research-backed supplement, from unregulated peptides marketed with unverified anti-aging and muscle growth promises, urging caution for patients.
NEWYou can now listen to Fox News articles!
We are officially living in the “maxxing” era.
From “looksmaxxing” to improve appearance to “sleepmaxxing” for better rest, these viral terms all point to the same goal: squeezing every ounce of potential out of a specific trait or habit.
With a growing focus on optimizing wellness and maximizing longevity, the trend has evolved into what’s known as “humanmaxxing,” sparking a bigger question: How far can people go to optimize the human body?
ANTI-AGING BENEFITS LINKED TO ONE SURPRISING HEALTH HABIT
While there is no single definition of humanmaxxing, the trend generally refers to efforts to optimize health, performance and longevity through a combination of lifestyle habits, health tracking, supplements and, in some cases, more experimental interventions.
While there is no single definition of humanmaxxing, the trend generally refers to efforts to optimize health, performance and longevity through a combination of lifestyle habits, health tracking, supplements and, in some cases, more experimental interventions. (iStock)
For some, the movement begins with biohacking. According to Dave Asprey, a Texas-based wellness expert who refers to himself as the “father of biohacking,” optimizing your body starts with changing your environment.
Asprey has defined biohacking as “the art and science of changing the environment around you or inside you so that you have full control of your own biology.”
COULD HUMANS LIVE TO BE 150 YEARS OLD? GENETICIST SHARES WHY IT MAY BE POSSIBLE
His public advice focuses on boosting cellular energy through everyday choices like intermittent fasting, high-fat diets, red-light therapy and supplement routines.
“My goal right now is 180 years, because I’m doing something about it now instead of waiting,” he once said.
Clinical experts warn that extreme self-experimentation skips the rigorous safety checks that typical medical science requires. (iStock)
Others have embraced a more data-driven approach. Tech entrepreneur Bryan Johnson, creator of the multimillion-dollar longevity project Blueprint in Los Angeles, argues that optimizing the body means removing human error from health decisions and instead relying on medical data.
“Methodically, we sought to build an algorithm with science and data that could better care for me than I can myself,” Johnson wrote on his website. “My mind did not have the authority to override the algorithm.”
THINKING ABOUT PEPTIDES? DOCTORS REVEAL KEY DOS AND DON’TS AS ‘WILD WEST’ MARKET GROWS
Johnson’s routine involves tracking hundreds of health metrics, eating a precisely measured diet, taking dozens of supplements, and undergoing advanced medical treatments in an effort to reduce his biological age.
CLICK HERE FOR MORE HEALTH STORIES
At the far end of the spectrum are those investing in technologies aimed at pushing the limits of human performance.
London-based tech investor Christian Angermayer recently described humanmaxxing as a strategy toward human maximization.
Tech entrepreneur Bryan Johnson, creator of the multimillion-dollar longevity project Blueprint, argues that optimizing the body means removing human error from health decisions and instead relying on medical data. (iStock)
“I don’t think we should become something different, because I think humans are awesome, but I think we can maximize the potential [that] is already in us,” he said in an interview with The New York Times.
Angermayer’s investment firm, Apeiron Investment Group, focuses on technologies intended to help people “live longer, healthier and more fulfilling lives.” He also founded atai Life Sciences, a biotechnology company that develops psychedelic treatments for mental health conditions that are currently being evaluated in clinical trials.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
As interest in humanmaxxing grows, mainstream health experts urge consumers to separate evidence-based wellness practices from experimental interventions.
Public guidance from the National Institute on Aging notes that while some anti-aging therapies have shown promise in laboratory research, there is not yet sufficient evidence that they can safely extend human life.
As interest in humanmaxxing grows, mainstream health experts urge consumers to separate evidence-based wellness practices from experimental interventions. (iStock)
Clinical experts also caution that extreme self-experimentation can bypass the rigorous safety standards applied to conventional medical treatments.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
According to the Endocrine Society, taking substances such as testosterone or growth hormone without a medical need can lead to serious health risks, including cardiovascular complications and long-term disruption of the body’s chemical balance.
While many humanmaxxing habits overlap with standard healthy lifestyle practices, experts say consumers should be cautious of expensive or experimental interventions that promise dramatic anti-aging or longevity benefits without strong scientific evidence.
NEWYou can now listen to Fox News articles!
A new test could make it easier to detect high-risk prostate cancer cases earlier.
The blood test, called Stockholm3, is showing promise in clinical trials, beating out the traditional, standard prostate-specific antigen (PSA) test.
In a new study published in the Annals of Internal Medicine, researchers from the Karolinska Institutet in Sweden studied the test’s efficacy in more than 12,000 men — mostly Swedish or European — aged 50 to 74.
NEW PROSTATE CANCER TEST PINPOINTS DISEASE BETTER THAN PSA OPTION, STUDY FINDS
All participants were tested with PSA and Stockholm3 and were followed for two years. During the follow-up period, 443 men were diagnosed with aggressive prostate cancer.
Stockholm3 detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests.
Stockholm3 detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests. (iStock)
Stockholm3 missed “significantly fewer” serious cancer cases than PSA. The number of men incorrectly classified as high-risk was similar across both tests, according to a press release.
Thorgerdur Palsdottir, a researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, wrote in a statement that one of the major challenges in prostate cancer is being able to identify the cases that are “truly dangerous.”
‘DILBERT’ CREATOR’S DESPERATE PLEA SHINES SPOTLIGHT ON ALTERNATIVE PROSTATE CANCER DRUG
“Our results show that Stockholm3 identifies significantly more aggressive cancer cases than PSA without increasing the number of unnecessary follow-ups,” she said.
“These results point toward a potential change in how prostate cancer screening can be conducted,” the researcher added. “A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures.”
“A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures,” a researcher commented. (iStock)
Study co-author Hari Vigneswaran, chief medical officer of Stockholm3-maker A3P Biomedical, commented on these “promising” findings in an interview with Fox News Digital.
PROSTATE CANCER SCREENING AFTER 70: EXPERTS QUESTION GUIDANCE AFTER BIDEN’S DIAGNOSIS
He confirmed that the PSA has been the standard for prostate cancer screening since the 1990s despite its “well-documented limitations.”
CLICK HERE FOR MORE HEALTH STORIES
“It leads to invasive and costly follow-up testing, contributes to over-diagnosis of non-aggressive cancers and, most importantly, it misses a substantial share of aggressive disease,” Vigneswaran said.
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival is close to 100%. (iStock)
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival rate is close to 100%, which highlights the importance of early detection, according to the doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Data from the National Cancer Institute’s SEER database show that metastatic prostate cancer has risen over the past decade, suggesting that “we have not improved early detection of the aggressive, curable disease that screening is meant to catch,” Vigneswaran said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The goal of screening is to find the cancers that need treatment while they are still curable, without raising the number of men who screen positive but don’t have aggressive disease,” he said.
Stockholm3 could reduce the need for unnecessary MRIs and biopsies, according to the researcher. (Getty Images)
Stockholm3 could reduce the need for unnecessary MRIs and biopsies, according to the researcher.
The findings did have some limitations. Stockholm3 is an investigational device and is not available for sale in the U.S., Vigneswaran noted.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The test estimates a man’s risk of aggressive prostate cancer, but a biopsy remains the gold standard for confirming the disease.
The company plans to seek FDA approval to use the test for routine screening and will “generate the evidence needed to support that pathway, including U.S. data,” Vigneswaran said.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
-
World3 minutes agoShipping giant warns Strait of Hormuz chaos is ‘new normal’ as Tehran shifts 4M barrels
-
Politics10 minutes agoJacob Frey praises Somali community as Minnesota faces renewed scrutiny over fraud investigations
-
Sports18 minutes agoJ.T. Poston posts a 12 on a single hole at Travelers Championship in stunning meltdown
-
Technology25 minutes agoMidjourney’s wild body scanner scans you in water
-
Business28 minutes agoWhy tech stocks are getting hammered
-
Entertainment33 minutes agoSigh. Again? ‘Love Island USA’ confirms another contestant fired over apparent use of racial slur
-
Politics43 minutes agoCommentary: This California bill is so bad it has me agreeing with a Trump Republican
-
Sports55 minutes agoWife, kids of Dodgers’ Miguel Rojas in Caracas when earthquakes hit Venezuela
